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Introduction
Aldehyde oxidase (AO) is a cytosolic molybdenum-containing hydroxylase that has rapidly ascended in recent years to be a drug-metabolizing enzyme of high relevance within drug discovery and development (Pryde et al., 2010; Garattini and Terao, 2011, 2012; Hutzler et al., 2013 ). This enzyme is comprised of two identical ~150 kDa subunits, is active as a homo-dimer, and demonstrates broad substrate selectivity, oxidizing a variety of aldehydes and azaheterocyclic-containing drug molecules (Beedham, 1987; Kitamura et al., 2006; Garattini et al., 2008) . Due to the subcellular location of this enzyme, metabolic stability investigations utilizing human liver microsomes fail to identify the contribution of AO-mediated metabolism to total metabolic clearance, which has led to early clinical failures for otherwise promising drug candidates. In particular, poor pharmacokinetic properties were observed following dosing of humans in phase I studies for drugs such as carbazeran, BIBX1382, and FK3453 (Kaye et al., 1984; Dittrich et al., 2002; Akabane et al., 2011) . In addition, an AO-mediated metabolite of SGX523 not identified pre-clinically was reported to cause acute renal toxicity due to extremely poor solubility and crystallization in the kidney (Diamond et al., 2010) . Unfortunately, all of these aforementioned examples of early clinical failures can be attributed to a lack of complete understanding of metabolic clearance mechanisms, due to in vitro metabolism studies only being conducted in microsomal liver fractions.
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6 the same donors (75 total donors). In addition, characteristics of tested donors were examined to understand the impact of demographic variables such as age, gender, ethnicity, medical history, and common single nucleotide polymorphisms (SNPs) on AO activity. AO enzymatic activity was estimated utilizing O 6 -benzylguanine (O 6 -BG) as the probe substrate ( Figure 1 ). O 6 -BG has been reported to be exclusively metabolized by AO-mediated oxidation to the 8-oxoguanine metabolite in cancer patients, where the area under the concentration vs. time curve (AUC) of the metabolite was 12 to 29-fold greater than parent O 6 -BG (Dolan et al., 1998) . In addition, we have demonstrated in our lab that when hydralazine, a selective inhibitor of AO (Strelevitz et al., 2012) , is co-incubated with O 6 -BG in cryopreserved hepatocytes, metabolism is effectively inhibited (Hutzler et al., 2012) . Thus, O 6 -BG appears to be a suitable probe substrate for estimating AO activity in hepatocytes. et al., 1999) . Three separate 10 million hepatocyte suspensions from each donor stored in DMEM-based medium (25% Viaspan ® ) were prepared for incubation and assessment of AO activity immediately following isolation (within 2 hours), ~24 hours post-isolation (incubations conducted at BioreclamationIVT), and ~24 hours post-isolation following shipment of hepatocytes to Boehringer-Ingelheim (common practice when ordering "fresh" hepatocytes from a vendor). Hepatocyte suspensions for ~24 hour post-isolation incubations conducted at
Materials and Methods
BioreclamationIVT were stored at 4°C without mixing to mimic shipping conditions. The remainder of the suspension from each donor was cryopreserved according to protocol used by BioreclamationIVT. Donor demographics are shown in 
Results
Effect of Time and Cryopreservation on Intrinsic Clearance in Hepatocytes from Ten
Donors. In vitro intrinsic clearance was determined utilizing O 6 -BG as a marker for AO activity immediately following isolation of fresh hepatocytes from intact livers (process for isolation and preparing for incubation takes ≤ 2 hours from receipt of liver), as well as ~24 hours postisolation, and following cryopreservation. Donors included seven males and three females, with ages ranging from 4-74 years (Table 2 ). Intrinsic clearance data for the ten donors is presented in Figure 2 . Overall, the data suggests that substantial loss in AO activity within the first 24
hours following isolation of hepatocytes is common (average loss of 42%, range 15-81% for 7/10 donors). Interestingly, this downward trend in activity was not observed for donors D3, D4, and D7, which suggests that loss of activity is likely donor-dependent. When comparing AO activity 24 hours post-isolation (stored at 4°C) to 24 hours in hepatocytes that were shipped overnight (mimicking process for how "fresh" hepatocytes are typically acquired), intrinsic clearance values were comparable for 5/10 donors, with measurably higher activity in donors D1, D2, D8, and D10 ( Figure 2) . Lastly, the effect of cryopreservation was evaluated using the same ten donors. Overall, activity in cryopreserved hepatocytes fairly well represented the activity observed in fresh hepatocytes that were isolated and incubated immediately for the same donors (within 81%, range 48-100%), which suggests that cryopreserved hepatocytes may be preferable from an activity standpoint compared to fresh hepatocytes that typically are at least 24 hours old prior to conduct of in vitro metabolism studies. Lastly, when comparing activity across the ten donors, high donor-to-donor variability was observed (5 to 8-fold) regardless of condition.
This article has not been copyedited and formatted. The final version may differ from this version. Table 1 ). The data for O 6 -BG intrinsic clearance across 75 donors is presented graphically in Figure 3 . First, it is worth noting that the activity observed in a lot of 19 pooled mixed-gender donors (Cl int = 34.2±1.4 mL/min/kg (n=4 replicates), dotted line in Figure 3 ) was less than ~63% the donors in the current 75 donor pool population. Also, the first 5 donors (LNE, JGM, GTD, GTV, and TYS) had unmeasurable AO activity as determined by substrate depletion. The cut-off used for extrapolation of half-life was ~790 minutes (e.g. half-life Overall, when comparing demographics such as gender, body mass index (BMI), ethnicity (African American, Hispanic, and Caucasian) and age (range 1-88), no statistically significant differences were observed with respect to activity when utilizing two-tailed t-test and 1-way ANOVA analysis (Figure 4 ).
With respect to disease factors, a history of diabetes was noted for 15 out of 75 donors (20%), but was a disease characteristic in donors spanning the entire range of activities (Table 1 in Supplemental Information). No additional trends were identified.
Single Nucleotide Polymorphism (SNP) Analysis. Single nucleotide polymorphism (SNP) data for 4 donors (JVA, UFN, BLC, and CNM) was unable to be collected due to lack of sufficient cells for DNA isolation following initial metabolism studies. Thus, known SNPs for AOX1 were analyzed in the donor population (n=71) using Taqman PCR assays (Table 3) . Four of the six SNPs tested were not detected in our donor population. Two SNPs for AOX1 (rs3731772 and rs55754655) were detected and showed allelic frequencies similar to those reported from other cohort studies such as the NHLBI Exome Sequencing Project (Table 4) .
However, the presence of these mutant alleles did not correlate with a statistically significant difference in intrinsic clearance values for rs55754655 (p=0.2502) or rs3731722 (p=0.0514) when compared to the wild-type group using a two-tailed t-test ( Figure 5 ).
This article has not been copyedited and formatted. The final version may differ from this version. cryopreservation on enzymatic activity. In addition, donor variability in the largest set of subjects reported to date (75 donors) was evaluated using cryopreserved human hepatocytes.
When a drug metabolism research lab orders fresh hepatocytes from a vendor, by the time they receive cells for incubations, they are at least 24 hours old (next day following isolation). Understanding the potential loss in AO activity over this time period is important, especially if using metabolism data for scaling and prediction of human metabolic clearance.
When in vitro intrinsic clearance was determined immediately following isolation of fresh hepatocytes from ten donor livers (within 2 hours post-isolation), and then measured again in the same cells roughly 24 hours following isolation, substantial loss in AO activity was observed (average loss of 42%, range 15-81%). Interestingly, this trend was dependent on the donor, as no activity loss was observed over this time period for donors D3, D4, and D7 (Figure 2 ). When evaluating the available donor characteristics, it was not clear why some donors displayed a loss in activity within the initial 24 hours, whereas others did not. Since all donor hepatocytes were treated the same, it is unlikely to be due to the process of cell isolation or storage over the initial 24 hours. One could plausibly suggest a link between the general health of the donor livers or cells and AO activity over time, but this is entirely speculative. Additional research utilizing more donors would need to be conducted to provide convincing evidence. When comparing activity of AO 24 hours post-isolation (e.g. stored) to hepatocytes that were shipped overnight (mimicking process for how "fresh" hepatocytes are typically acquired), intrinsic clearance values were overall comparable, but with a currently unexplained increase of activity for donors D1, D2, D8 and D10 following shipment and incubation (Figure 2 ). The impact of cryopreservation was also evaluated using the same ten donors. Overall, activity in cryopreserved hepatocytes fairly well represented the activity observed in hepatocytes that were isolated and incubated immediately for the same donors (within 81%, range 48-100%), which suggests that cryopreserved hepatocytes would be preferable to fresh hepatocytes that commonly are at least 24 hours old prior to conduct of in vitro metabolism studies. This is further rationalized when one considers the variability in activity loss observed over the initial 24 hours, and the uncertainty around availability of fresh donor hepatocytes. A similar evaluation was undertaken by Akabane and colleagues , where they compared activity for various non-P450 enzymes in fresh and cryopreserved hepatocytes. Aldehyde oxidase was among the non-P450 enzymes tested, and they used multiple probe substrates to estimate activity, including ODMD #57984
1 6 activity than fresh hepatocytes . It is worth noting that the "fresh" hepatocytes used in their studies were acquired from multiple vendors in the traditional manner (e.g. ordered and shipped next day). Although speculative, it may be possible based on our observations that substantial AO activity was lost during the isolation and shipment time, which could explain the higher activity observed in cryopreserved hepatocytes from the same donor.
When comparing activity across the ten donors, regardless of whether comparing the intrinsic clearance values in fresh or cryopreserved hepatocytes, donor variability was observed (5 to 8-fold). Several reports in the literature demonstrate high donor-to-donor variability for AO activity, although the magnitude appears substrate-and methodology-(e.g. metabolite formation or substrate depletion) dependent ( Table 1 ). Given that cryopreserved hepatocytes from the ten donors tested appear to possess comparable activity to hepatocytes that were immediately incubated following isolation, use of cryopreserved hepatocytes was determined to be suitable for evaluating variation in AO activity across a larger donor pool (n=75 donors), where characteristics (e.g. gender, age, ethnicity, and medical history) could be evaluated in effort to elucidate potential causes for this variation. To our knowledge, this represents the largest donor pool from which variability in activity has been assessed, in particular, using human hepatocytes.
Overall, activity for the 75 tested donors varied by at least 17-fold, with the lowest activity being DMD #57984
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extensive alcohol abuse up until time of death. This acute effect of alcohol abuse was also recently reported by scientists at Pfizer (Fu et al., 2013) . The exact mechanism of this alcohol effect on AO activity was not elucidated, although it was found that AOX1 protein expression level appeared unaffected, despite significant decreases in enzyme activity (Fu et al., 2013) .
Thus, the presence of AO protein apparently does not correlate with activity, which complicates the assessment of variability factors. Fu and colleagues suggest that several additional factors may contribute to variable or low AO activity, including disruption of active homo-dimer formation, and molybdenum (Mo) cofactor deficiency (Fu et al., 2013) . Meanwhile, in our studies, other donors with a history of alcohol abuse that abstained from alcohol years prior to death (donors ORM and CNM), demonstrated moderate (45.3 ± 4.9 mL/min/kg) to high (77 ± 13 mL/min/kg) AO activity, suggesting that the alcohol effects may be more acute in nature. This finding is worthy of additional research, as there could be pharmacokinetic/pharmacodynamic drug interaction implications for alcoholics taking any drug that has a predominant clearance mechanism through AO.
In addition to donor demographics and medical histories, another potential contributor to variable AO activity is the presence of single nucleotide polymorphisms (SNPs), which are known and have been reported (Smith et al., 2009; Hartmann et al., 2012; Kurzawski et al., 2012) . While the two variants observed in our donor population (rs55754655 and rs3731722) rs3731722 (H1297R) led to 2-to 4-fold higher catalytic activities, but this conclusion was derived using purified expressed AO enzyme, and thus was independent of additional donor variable factors. When considering all of the aforementioned factors involved in impacting AO activity (Mo deficiency, etc.), it is unlikely that genotype alone dictates the phenotypic activity of AO. While this SNP analysis was limited in scope, this premise is supported by a recent report where variability in XK469 clearance was found to be independent of AOX1 polymorphisms (Ramirez et al., 2013) .
In summary, it has been demonstrated that "fresh" hepatocytes obtained from a vendor, which are in reality at least 24 hours old, may have lost substantial AO activity depending on donor, whereas cryopreserved hepatocytes appear to better represent the activity in a donor liver when incubations are conducted immediately following isolation of hepatocytes. Thus, cryopreserved human hepatocytes appear to be a suitable in vitro model for determining intrinsic clearance activity for substrates of AO as part of an integrated approach to understanding total metabolic clearance. In addition, there is substantial donor-to-donor variability for AO activity, which requires careful characterization of donors or donor pools when selecting hepatocyte lots that contain adequate activity for the multitude of drug-metabolizing enzymes. Since it appears that multiple factors may contribute to variable or low AO activity, it is not recommended to use hepatocytes from a single donor to estimate AO activity, especially if alcohol abuse is noted in the donor medical history. Instead, pre-screening donors for AO activity, and creating a custom high-activity pooled lot of cryopreserved hepatocytes is advised to minimize under-prediction of metabolic clearance in human.
This article has not been copyedited and formatted. The final version may differ from this version. groups utilizing two-tailed t-test. In addition, no significant differences in activity were observed between race (C) and various age groups (D) using 1-Way ANOVA with Bonferroni's Multiple
Comparison test (p>0.05). 
